Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Buy" by Analysts

Key Points

• Humacyte, Inc. has received a consensus rating of "Buy" from analysts, with an average 12-month price target of $10.64.
• Director Brady W. Dougan and CEO Laura E. Niklason both sold 1.1 million shares at an average price of $1.63, resulting in a 65.02% decrease in their ownership.
• For the last quarter, Humacyte reported earnings of ($0.24) per share, missing analyst estimates, with revenues of only $0.30 million compared to expectations of $0.94 million.

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have earned an average rating of "Buy" from the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $9.75.

A number of equities analysts have commented on the company. D. Boral Capital reissued a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a research note on Monday, August 11th. TD Cowen dropped their price objective on shares of Humacyte from $5.00 to $3.50 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Wall Street Zen cut shares of Humacyte from a "hold" rating to a "sell" rating in a research report on Sunday, August 17th. Benchmark dropped their price objective on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Finally, HC Wainwright dropped their price objective on shares of Humacyte from $4.00 to $3.00 and set a "buy" rating for the company in a research report on Tuesday, August 12th.

Humacyte Price Performance

Humacyte stock traded down $0.03 on Tuesday, reaching $1.55. The company's stock had a trading volume of 2,383,065 shares, compared to its average volume of 5,907,176. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.93 and a current ratio of 2.45. The company has a market cap of $245.47 million, a price-to-earnings ratio of -3.44 and a beta of 1.88. The business's fifty day moving average price is $2.14 and its 200 day moving average price is $2.25. Humacyte has a twelve month low of $1.15 and a twelve month high of $6.77.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.94 million. Equities analysts expect that Humacyte will post -1.27 earnings per share for the current fiscal year.

Insider Activity at Humacyte

In related news, CEO Laura E. Niklason sold 1,100,000 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $1.63, for a total value of $1,793,000.00. Following the completion of the transaction, the chief executive officer owned 591,685 shares in the company, valued at $964,446.55. The trade was a 65.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Brady W. Dougan sold 1,100,000 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $1.63, for a total transaction of $1,793,000.00. Following the completion of the transaction, the director owned 591,685 shares of the company's stock, valued at $964,446.55. This trade represents a 65.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 4,482,090 shares of company stock valued at $7,466,382 in the last 90 days. 5.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Humacyte

Several institutional investors and hedge funds have recently made changes to their positions in HUMA. Wells Fargo & Company MN raised its position in shares of Humacyte by 40.9% during the 4th quarter. Wells Fargo & Company MN now owns 50,454 shares of the company's stock valued at $255,000 after acquiring an additional 14,649 shares during the last quarter. Legal & General Group Plc raised its position in shares of Humacyte by 19.5% during the 4th quarter. Legal & General Group Plc now owns 81,405 shares of the company's stock valued at $411,000 after acquiring an additional 13,293 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Humacyte during the 4th quarter valued at $377,000. XTX Topco Ltd raised its position in shares of Humacyte by 29.0% during the 4th quarter. XTX Topco Ltd now owns 43,929 shares of the company's stock valued at $222,000 after acquiring an additional 9,880 shares during the last quarter. Finally, First Trust Advisors LP bought a new stake in shares of Humacyte during the 4th quarter valued at $1,720,000. Institutional investors own 44.71% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.